Enliven Therapeutics, Inc. (ELVN) Financial Statements
Free cash flow over the same period: -$67.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ELVNEnliven Therapeutics, Inc.Follow ELVN — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 32.2 | 38.4 | 31.0 | 64.6 | 80.8 | 85.9 | 89.2 | |
| Operating income | -41.7 | -51.4 | -38.8 | -83.5 | -104.6 | -119.7 | -124.4 | |
| Pre-tax income | — | — | 1.6 | -71.6 | -88.8 | -103.7 | — | |
| Income tax | — | — | 0.0 | 0.0 | 0.2 | 0.0 | — | |
| Net income | -41.4 | -51.4 | -37.7 | -71.6 | -89.0 | -103.7 | -105.9 | |
| Diluted EPS ($) | -3.53 | -2.37 | -12.05 | -2.01 | -1.89 | -1.83 | -1.60 | |
| Diluted shares (mn) | — | — | 3.1 | 35.5 | 47.1 | 56.7 | — |
USD millions · SEC XBRL
Enliven Therapeutics, Inc. — questions
- What is Enliven Therapeutics, Inc.'s net income?
- -$105.9M over the twelve months to 2026-06-30.
- What is Enliven Therapeutics, Inc.'s free cash flow?
- -$67.0M over the twelve months to 2026-06-30.
- What are Enliven Therapeutics, Inc.'s diluted earnings per share?
- $-1.60 over the twelve months to 2026-06-30.
Every figure on this page comes from Enliven Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.